Antimalarial drug discovery: progress and approaches
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Recent antimalarial drug discovery has been a race to produce new medicines that overcome emerging drug resistance, whilst considering safety and improving dosing convenience. Discovery efforts have yielded a variety of new molecules, many with novel modes of action, and the most advanced are in late-stage clinical development. These discoveries have led to a deeper understanding of how antimalarial drugs act, the identification of a new generation of drug targets, and multiple structure-based chemistry initiatives. The limited pool of funding means it is vital to prioritize new drug candidates. They should exhibit high potency, a low propensity for resistance, a pharmacokinetic profile that favours infrequent dosing, low cost, preclinical results that demonstrate safety and tolerability in women and infants, and preferably the ability to block Plasmodium transmission to Anopheles mosquito vectors. In this Review, we describe the approaches that have been successful, progress in preclinical and clinical development, and existing challenges. We illustrate how antimalarial drug discovery can serve as a model for drug discovery in diseases of poverty. Malaria case numbers are rising globally and there is a vital need for new medicines that overcome the emergence of drug resistance. This Review describes the current landscape of small-molecule antimalarial therapies and the methods used to discover them as well as perspectives on approaches to find new targets and treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spread of Artemisinin Resistance in Plasmodium falciparum Malaria
Ashley, E. A., Dhorda, M., Fairhurst, R. M., Amaratunga, C., Lim, P., Suon, S., Sreng, S., Anderson, J. M., Mao, S., Sam, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314981 · Cited by 2,205
Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018
Wouters, O. J., McKee, M., & Luyten, J. (2020) · JAMA · doi:10.1001/jama.2020.1166 · Cited by 1,531
Qinghaosu (Artemisinin): The Price of Success
White, N. J. (2008) · Science · doi:10.1126/science.1155165 · Cited by 954
Ashley, E. A., Pyae Phyo, A., & Woodrow, C. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30324-6 · Cited by 553
Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention
Chandramohan, D., Zongo, I., Sagara, I., Cairns, M., Yerbanga, R.-S., Diarra, M., Nikièma, F., Tapily, A., Sompougdou, F., Issiaka, D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2026330 · Cited by 236
Combining malaria vaccination with chemoprevention: a promising new approach to malaria control.
Greenwood, B., Cairns, M., Chaponda, M., Chico, R. M., Dicko, A., Ouedraogo, J.-B., Phiri, K. S., ter Kuile, F. O., & Chandramohan, D. (2021) · Malaria Journal · doi:10.1186/s12936-021-03888-8 · Cited by 32
Metadata
- Authors
- Siqueira-Neto, J. L., Wicht, K. J., Chibale, K., Burrows, J. N., Fidock, D. A., & Winzeler, E. A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2023-08-31
- Volume
- 22
- Issue
- 10
- Pages
- 807-826
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W4386333116
- Cited by
- 240
- References
- 6
- FWCI
- 15.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antimalarial drug discovery: progress and approaches. https://app.cochat.ai/papers/10.1038/s41573-023-00772-9
- The paper
- Siqueira-Neto, J. L., Wicht, K. J., Chibale, K., Burrows, J. N., Fidock, D. A., & Winzeler, E. A. (2023). Antimalarial drug discovery: progress and approaches. Nature Reviews Drug Discovery. https://doi.org/10.1038/s41573-023-00772-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.